Shares in ASX biotech companies Anteotech Ltd (ASX: ADO), Imugene Ltd (ASX: IMU) and Little Green Pharma Ltd (ASX: LGP) have all posted exciting gains over the past 12 months.
Let's have a look at the share price performance and recent news of all 3 ASX shares.
Little Green Pharma
At the time of writing, shares in this cannabis manufacturing and distribution company have climbed 121.1% over the course of 1 year. Little Green Pharma shares are also 15.33% up on the previous 5 days and 17.91% on the previous month.
Over the year-to-date, the company's shares have posted a return of 41%, having come off a high of 94 cents on 4 February 2021.
Over the previous 6 months, the company has reported 2 major announcements, including a firm purchase order from Denmark company Demecan for 9,000 units of flower, and signing an exclusive distribution deal with leading Polish pharmaceutical group Pelion SA.
With a share price of 79.5 cents at the time of writing, Little Green Pharma has a market capitalisation of $104.6 million, and currently has negative earnings per share.
Anteotech
The Anteotech share price has climbed 159% this year-to-date, however is 1.72% down at the time of writing.
Over the previous 5 days, Anteotech shares have gained 26.67%, giving the company a market capitalisation of around $556 million. Shares are trading off their 52-week high of 49.5 cents, but are above the 52-week low of 2 cents.
Over the year-to-date, the company has procured a specified manufacturing line in Brisbane as part of its EuGeni Test Strip Manufacturing Strategy, forming part of a "decentralised and diversified global manufacturing approach".
This technology provides rapid screening and identification of COVID-19 using a nasal sample. The company expects an additional capacity of 12 million strips per annum as a result of the new manufacturing line.
Imugene
The Imugene share price has surged by 277% year-to-date, recently down from a high of 49 cents, coming in today at 38 cents at the time of writing.
The immuno-oncology company is up 4.05% intraday, and has gained 10% over the previous 5 days. Imugene's market capitalisation has now reached $1.8 billion, but it has experienced a 1-month drop of 17% from the previous month.
Over the previous 6 months, the company has presented a series of positive data on clinical trial outcomes. Back in April 2021, the company released positive headline results for its phase 2 gastric cancer clinical trial.
Furthermore, on 18 May 2021, the company also announced the commencement of a phase 1 clinical trial in 2022 to expand on Imugene's expertise in oncolytic virus and cell therapy technology, for investigation in therapy for solid tumours.
Foolish takeaway
These 3 ASX biotech shares have each outperformed the broader Australian index this year, posting returns above the S&P/ASX 200 Index (ASX: XJO)'s 11% year-to-date.
